Re: License agreement between Pipex Therapeutics, Inc. and Meda ABAdeona Pharmaceuticals, Inc. • May 11th, 2010 • Pharmaceutical preparations
Pipex Therapeutics, Inc. (“Pipex”) proposes to enter into a license agreement (the “Meda License”) with Meda AB (“Meda”) whereby Pipex would grant to Meda a license to further develop and commercialize flupirtine for use in the treatment of fibromyalgia under certain rights and licenses granted to Pipex by The McLean Hospital Corporation (d/b/a “McLean Hospital”) (“McLean”) pursuant to a certain License Agreement between Pipex and McLean dated as of November 17, 2005, as amended by amendments effective September 17, 2007 and April 28, 2010 (the “McLean License”).
SUBLICENSE AGREEMENT BETWEEN MEDA AB AND PIPEX THERAPEUTICS, INC. May 6, 2010Sublicense Agreement • May 11th, 2010 • Adeona Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Sublicense Agreement (this “Agreement”) is entered into as of May 6, 2010 (the “Effective Date”) by Meda AB, a company organized under the laws of Sweden (“Meda”); Adeona Pharmaceuticals, Inc. a Nevada corporation (“Adeona”) and Pipex Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, USA (“Pipex”), a wholly owned subsidiary of Adeona. Meda, Adeona and Pipex are referred to individually as a “Party” and collectively as the “Parties”.
